RORγ

RORγ Related Products (27):

By Type:	Pan (1) Selective (17)
By Effects:	Inhibitors (10) Agonists (3) Antagonists (9) Activator (1) Modulators (3)

Cat. No.	Product Name	Effect	Purity

HY-120210

XY018	Antagonist	99.90%
XY018 is a potent ROR-γ-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC₅₀, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD).

HY-139780

JNJ-61803534	Inhibitor	99.88%
JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC₅₀ of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions.

HY-19775

GNE-6468	Antagonist	98.04%
GNE-6468 is a highly potent and selective RORγ (RORc) inverse agonist with an EC₅₀ value of 13 nM for HEK-293 cell. GNE-6468 exhibits an EC₅₀ of 30 nM for IL-17 PBMC.

HY-113345

Zymostenol	Agonist	99.33%
Zymostenol (5a-Cholest-8-en-3b-ol) is a late-stage precursor in the biosynthesis of cholesterol. Zymostenol is a RORγ agonist (EC₅₀: 1 μM).

HY-163436

F44-A13	Antagonist
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC₅₀ value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders.

HY-163611

XY039	Agonist
XY039 (compound 13e) is a RORγ inverse agonist with the IC₅₀ of 0.55 μM. XY039 induces cell apoptosis and shows antiproliferative activity in vivoand in vitro.

HY-168179

RORγt inverse agonist 32	Inhibitor
RORγt inverse agonist 32 (compound b14) is orally active. RORγt inverse agonist 32 can be used in inflammation research.

HY-16983

GNE-3500	Antagonist
GNE-3500 is a selective, orally active antagonist for Retinoic Acid Receptor-Related Orphan Receptor C (RORc, also known as RORγ or NR1F3) with an EC₅₀ of 12 nM. GNE-3500 exhibits good pharmacokinetic characteristics in rats.

HY-131338

RORγt inverse agonist 13	Inhibitor	98.13%
RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved agent-like properties, with an IC₅₀ of 63.8 nM.

HY-120785

SR1555	Antagonist	99.69%
SR1555 is a specific retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inverse agonist with an IC₅₀ value of 1 μM. SR1555 not only inhibits TH17 cell development and function but also increases the frequency of T regulatory cells, as well as inhibits the expression of IL-17. SR1555 can be used for researching autoimmune diseases.

HY-103637A

Vimirogant hydrochloride	Inhibitor	98.39%
Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor (K_i=3.5 nM; IC₅₀=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC₅₀=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant hydrochloride has the potential for autoimmune disorders research.

HY-133552

RORγt Inverse agonist 10	Antagonist	99.13%
RORγt Inverse agonist 10 is a potent and orally bioavailable RORγt (retinoic acid receptor-related orphan nuclear receptor gamma t) inverse agonist, with an IC₅₀ of 51 nM. RORγt is a major transcription factor of genes related to psoriasis pathogenesis such as IL-17A, IL-22, and IL-23R

HY-119366

S18-000003	Inhibitor	99.31%
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC₅₀ of <30 nM towards human RORγt in competitive binding assays. S18-000003 shows selectivity for RORγt over other ROR family members (IC₅₀>10 μM). S18-000003 can be used for the research of psoriasis with low risk of thymic aberrations.

HY-138115

7ß,27-Dihydroxycholesterol	Activator	≥99.0%
7ß,27-Dihydroxycholesterol (7β, 27-OHC) is a potent and selective activator of RORγt (K_i=120 nM). 7ß,27-Dihydroxycholesterol promotes the differentiation of mouse and human CD4⁺ Th17 cells. 7ß,27-Dihydroxycholesterol also increases the production of IL-17 depended on CYP27A1.

HY-136527

BMS-986251	Antagonist
BMS-986251 is an orally active and selective RORγt inverse agonist with an EC₅₀ of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC₅₀ of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced (HY-B0180) models (preclinical models of psoriasis).

HY-126252

A-9758	Inhibitor
A-9758 is a RORγ ligand and a potent, selective RORγt inverse agonist (IC₅₀=5 nM), and exhibits robust potency against IL-17A release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function. A-9758 significantly attenuates IL-23 driven psoriasiform dermatitis and is effective in blocking skin and joint inflammation.

HY-115879

SHR168442	Modulator
SHR168442 is a modulator of retinoid-related orphan receptor gamma (RORγ) with an IC₅₀ value of 0.035 μM.

HY-163192

W6134	Inhibitor	99.90%
W6134 is highly potent and selective RORγ covalent inhibitor with IC₅₀ of 0.21 μM. W6134 exhibits superior activity ini nhibiting the proliferation and colony formation and inducing apoptosis. W6134 can be used for the research of cancer.

HY-142940

RORγt modulator 5	Modulator
RORγt modulator 5 is a RORγt modulator with a K_i value of <100 nM. RORγt modulator 5 has the potential for inflammatory, metabolic, autoimmune and other diseases mediated by RORy study (WO2017132432A1; compound 2).

HY-142939

RORγt modulator 4	Modulator
RORγt modulator 4 is a RORγt modulator. RORγt modulator 4 has an activity to modulate IL-17A production in cells derived from mouse spleen (WO2018030550A1; compound 146).

Name
Email *

	Sorry, but the email address you supplied was invalid.